| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0140-6736(90)92416-F |
| P433 | issue | 8721 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 955-959 | |
| P577 | publication date | 1990-10-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Contraceptive efficacy of testosterone-induced azoospermia in normal men | |
| P478 | volume | 336 |
| Q36258057 | 7 Testicular steroidogenesis and androgen use and abuse |
| Q34364690 | 7 alpha-methyl-nortestosterone (MENT): the optimal androgen for male contraception |
| Q34275005 | A Clinical Trial of 7α-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men |
| Q37755705 | A hormonal contraceptive for men: how close are we? |
| Q71169930 | A male contraceptive pill |
| Q93883567 | A male contraceptive pill |
| Q72036023 | A non‐human primate study (baboon; Papio hamadryas) to determine if a long‐acting progestogen, levonorgestrel butanoate, combined with a long‐acting androgen, testosterone buciclate, can suppress spermatogenesis: I. Dose‐finding study |
| Q35162657 | A review of androgen-progestin regimens for male contraception |
| Q47933850 | A time-resolved fluorescence immunoassay for the measurement of testosterone in saliva: monitoring of testosterone replacement therapy with testosterone buciclate |
| Q49052223 | Ability of spermatozoa to bind to the zona pellucida during oligozoospermia induced with testosterone during a male contraceptive trial |
| Q34142577 | Acceptability of contraception for men: a review |
| Q26747149 | Adult-Onset Hypogonadism |
| Q56998406 | Advances in male hormonal contraception |
| Q36221968 | Advances in male hormone substitution therapy |
| Q73405643 | Altered molecular dynamics and antioxidant status in the spermatozoa in testosterone-induced oligospermia in mouse |
| Q42668582 | An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. |
| Q40669253 | Anabolic-androgenic steroids--a double-edged sword? |
| Q41262041 | Androgen use by athletes: a reevaluation of the health risks |
| Q48779669 | Androgens and male sexual behavior from mice to men. |
| Q24648373 | As the world grows: contraception in the 21st century |
| Q44187016 | CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception |
| Q34118838 | Characteristics associated with suppression of spermatogenesis in a male hormonal contraceptive trial using testosterone and Nestorone(®) gels. |
| Q37798945 | Clinical trials in male hormonal contraception |
| Q43818131 | Combination of subcutaneous levonorgestrel implants and transdermal dihydrotestosterone gel for male hormonal contraception |
| Q40393705 | Contraceptive choices: is the future with men? |
| Q50612224 | Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. |
| Q28243014 | Control of spermatogenesis in primate and prospect of male contraception |
| Q35207734 | Deciphering the pathways of germ cell apoptosis in the testis |
| Q34317005 | Deciphering the selective androgen receptor modulators paradigm |
| Q36196835 | Delivery options for contraceptives |
| Q38062951 | Demand for male contraception |
| Q31447673 | Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. |
| Q35172636 | Development of methods of male contraception: impact of the World Health Organization Task Force |
| Q34249428 | Developments in the control of testicular function |
| Q72332393 | Dose effects of the gonadotropin-releasing hormone antagonist, Nal-Glu, combined with testosterone enanthate on gonadotropin levels in normal men |
| Q36576954 | Drug insight: Recent advances in male hormonal contraception. |
| Q34433984 | Effect of increased scrotal temperature on sperm production in normal men. |
| Q51047124 | Effect of testosterone enanthate on serum lipoproteins in man. |
| Q51560853 | Effects of long-term administration of testosterone enanthate on glucose metabolism in rhesus monkeys. |
| Q70823592 | Effects of testosterone buciclate on testicular and epididymal sperm functions in bonnet monkeys (Macaca radiata) |
| Q44692016 | Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. |
| Q73258750 | Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception |
| Q53930873 | Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. |
| Q34341898 | Endocrine regulation of testicular function in men: implications for contraceptive development |
| Q73342658 | Evaluation of efficacy, safety, and reversibility of combination regimen of cyproterone acetate and testosterone buciclate in bonnet monkey |
| Q33959659 | Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. |
| Q44614878 | Expression of Bcl-2 and Bax in rhesus monkey testis during germ cell apoptosis induced by testosterone undecanoate |
| Q44223715 | Expression of Hsp70-2 in rhesus monkey testis during germ cell apoptosis induced by testosterone undecanoate |
| Q43945047 | Expression of P16(INK4a) in testis of rhesus monkey during heat stress and testosterone undecanoate induced azoospermia or oligozoospermia |
| Q42687248 | Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. |
| Q37788625 | Family Planning: Today and in the Future |
| Q40612198 | Family planning needs: new opportunities, emergency contraception and other new technologies. |
| Q90463773 | Fertility Preservation in Male to Female Transgender Patients |
| Q47351245 | High dose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood? |
| Q34135231 | Hormonal approaches to male contraception |
| Q71060611 | Hormonal contraception for men. The Task Force on Methods for the Regulation of Male Fertility |
| Q44123496 | Hormonal male contraception: end of a dream or start of a new era? |
| Q36815280 | Hormonal male contraception: progress and prospects for the 21st century |
| Q28468577 | Hormonal, chemical and thermal inhibition of spermatogenesis: contribution of French teams to international data with the aim of developing male contraception in France |
| Q74150245 | Immature spermatids are not prevalent in semen from men who are receiving androgen-based contraceptive regimens |
| Q51008551 | Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. |
| Q72115305 | Induction of spermatogenesis with gonadotrophins in Chinese men with hypogonadotrophic hypogonadism |
| Q44223706 | Investigation of a novel preparation of testosterone decanoate in men: pharmacokinetics and spermatogenic suppression with etonogestrel implants |
| Q53035337 | It is time for new male contraceptives! |
| Q38981727 | Male Contraception: Research, New Methods, and Implications for Marginalized Populations |
| Q26767429 | Male Hormonal Contraception: Where Are We Now? |
| Q36541199 | Male contraception: a realistic option? |
| Q34388609 | Male contraception: history and development |
| Q21710738 | Male hormonal contraception |
| Q38750063 | Male hormonal contraception: hope and promise |
| Q36479889 | Male hormonal contraception: looking back and moving forward |
| Q37872647 | Male hormonal contraception: potential risks and benefits |
| Q40491620 | Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. |
| Q73164655 | Male infertility |
| Q34089796 | New contraceptive methods |
| Q46016872 | Oligozoospermia induced by exogenous testosterone is associated with normal functioning residual spermatozoa. |
| Q44013158 | Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. |
| Q35539199 | Pharmacologic development of male hormonal contraceptive agents. |
| Q36179775 | Pharmacological developments in male contraception |
| Q31437280 | Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function |
| Q24645334 | Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception |
| Q40500151 | Prospects for new hormonal male contraceptives. |
| Q47399237 | Prostate-specific antigen and prostate gland size in men receiving exogenous testosterone for male contraception |
| Q51091872 | Psychosexual effects of three doses of testosterone cycling in normal men. |
| Q83227216 | Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis |
| Q33637756 | Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease |
| Q34646568 | Recent advances in hormonal male contraception |
| Q34191776 | Recent methodological advances in male hormonal contraception |
| Q35534699 | Reproductive endocrinology: Male hormonal contraceptive passes efficacy test in China |
| Q43755667 | Residual sperm function in oligozoospermia induced by testosterone enanthate administered as a potential steroid male contraceptive. |
| Q33322318 | Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men |
| Q46951247 | Significant impact of 5alpha-reductase type 2 polymorphisms on sperm concentration and motility |
| Q33800970 | Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive |
| Q70494772 | Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men |
| Q36745093 | Sperm function in Indonesian men treated with testosterone enanthate |
| Q24201286 | Steroid hormones for contraception in men |
| Q24245039 | Steroid hormones for contraception in men |
| Q24246673 | Steroid hormones for contraception in men |
| Q44356945 | Structure-activity relationship study of human liver microsomes-catalyzed hydrolysis rate of ester prodrugs of MENT by comparative molecular field analysis (CoMFA). |
| Q38822095 | Testosterone and Male Infertility |
| Q37834058 | Testosterone and the child (0-12 years) with Klinefelter syndrome (47XXY): a review |
| Q55066488 | Testosterone decreases lipoprotein(a) in men. |
| Q33913912 | Testosterone therapy in men: clinical and pharmacological perspectives |
| Q30668764 | The effects of feeding an Asian or Western diet on sperm numbers, sperm quality and serum hormone levels in cynomolgus monkeys (Macaca fascicularis) injected with testosterone enanthate (TE) plus depot medroxyprogesterone acetate (DMPA). |
| Q38722243 | The impact of drugs on male fertility: a review. |
| Q35604296 | Trends in male contraception |
| Q37718605 | Update on male hormonal contraception: is the vasectomy in jeopardy? |
| Q35871918 | Update on the male hormonal contraceptive agents |
| Q35070763 | Urologic aspects of andropause |
| Q35605057 | Use of progestins in male contraception |
| Q80295513 | [Non-deferential male contraception: review of the literature] |
| Q53636345 | [Therapeutic issues concerning male fertility]. |
Search more.